HRT Financial’s Eterna Therapeutics ERNA Stock Holding History

HRT Financial’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-505	Closed	-$15K	–	4042
2025 Q4	$15K	Buy	+505	New	+$17.2K	﹤0.01%	3016
2025 Q2	–	Sell	-113	Closed	-$7K	–	2876
2025 Q1	$7K	Buy	+113	New	+$13.9K	﹤0.01%	2379

Other funds holding ERNA

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Corient Private Wealth Miami, Florida $78.6B AUM 28.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

WAM

Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial's ERNA Position: Q1 2026 in Review

HRT Financial sold out of Eterna Therapeutics (ERNA) in Q1 2026, closing a stake of 505 shares — an estimated $15K sold.

HRT Financial first reported a position in ERNA in Q1 2025 and held it in 2 quarters. The position peaked at $15K in Q4 2025. 15 funds tracked by Wall St. Rank hold ERNA as of Q1 2026.

HRT Financial reported no remaining Eterna Therapeutics position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 505 Eterna Therapeutics shares in Q1 2026, an estimated $15K.
HRT Financial first reported a position in Eterna Therapeutics in Q1 2025 and held it in 2 quarters.
HRT Financial's Eterna Therapeutics position peaked at $15K in Q4 2025.
15 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.